Malignant Bone Marrow Neoplasm

In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the A… (full text at CIViC)

PMID 19487385 · Apperley et al., 2009 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the M244V secondary variant in 12/12 bacterial clones generated… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achi… (full text at CIViC)

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing an M244V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.3 nmol/L vs. 0.8… (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had only a partial … (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

One chronic myeloid leukemia patient in chronic phase had no response to imatinib. Bacterial clones generated using peripheral blood RNA later revealed the BCR-ABL1 fusion with the M244V secondary var… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In a study of 39 chronic phase CML patients with BCR-ABL variants, M244V was seen in 3 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine … (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 5 had M244V mutations

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

A chronic myelogenous leukemia patient with a M244V mutation in the ABL1 portion of the BCR-ABL1 fusion was associated with response to nilotinib monotherapy. Prior to detection of the M244V mutation,… (full text at CIViC)

PMID 26622510 · Shen et al., 2015 · Open in CIViC

In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with t… (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

In an in vitro study, pro-B Ba/F3 cell line expressing M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 920.2nM),… (full text at CIViC)

PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC

In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with t… (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

In an in vitro study, pro-B Ba/F3 cell line expressing a compound mutant of both V299L and M351T mutations in the ABL1 portion of the BCR-ABL1 fusion protein demonstrated increased sensitivity to axit… (full text at CIViC)

PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with Y253H, M388L, and M388L/M244V variants in 4/10, 5/10, and 1/10 … (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with G250E/E138G/I242T/K271R/V338M, G250E/E138G/I242T/K271R, G25… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In a retrospective study of 118 imatinib-resistant or -intolerant, Philadelphia chromosome BCR-ABL1 fusion positive, chronic myeloid leukemia (chronic phase) patients, patients with mutations in the A… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In a study of 39 chronic phase CML patients with BCR-ABL variants, N336S was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with t… (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

In an in vitro study, pro-B Ba/F3 cell line expressing Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 967.4nM),… (full text at CIViC)

PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC